Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06802835

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

EGFR Antibody Combined With Programmed Death-1 Inhibitor and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Multi-center, Phase I/II Clinical Trial

Sponsor: Sun Yat-Sen University Cancer Center

Conditions Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) Recurrent Nasopharynx Carcinoma

Interventions EGFR Antibody Gemcitabine, Cisplatin IMRT PD-1 antibody

Updated 3 times since 2025 Last updated: May 13, 2025 Started: May 31, 2025 Primary completion: Feb 20, 2027 Completion: Feb 20, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06802835, this PHASE1/PHASE2 trial focuses on Metastatic Nasopharyngeal Carcinoma and Nasopharyngeal Cancinoma (NPC) and remains actively recruiting participants. Sponsored by Sun Yat-Sen University Cancer Center, it has been updated 3 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen University Cancer Center

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China